Another week passed, and still no word whether the Supreme Court will hear a decision originating in the Federal Circuit, that could have an effect on how soon generic versions of a drug show up on the market, reports Reuters. And in more recent Federal Circuit jurisprudence, the court looks at overtime compensation for Federal Aviation Administration ("FAA") air-traffic control specialists.
Teva et al., v. Sandoz, Inc., et al.
Teva manufactures Copaxone, a multiple-sclerosis drug, and has been seeking to delay introduction of generic competing drugs. In a patent infringement claim against Novartis's Sandoz, Mylan and Momenta, the Federal Circuit "upheld four Teva patents that expire in May while invalidating a separate patent that would have blocked generic competition until September 2015," according to Bloomberg.